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Sm_nuary The effects of the timing of operation in relation to menstrual phase and hormone receptor protein
positivity and concentration of the 5 year survival of 267 premenopausal women with operable breast cancer
were evaluated. The patients were treated in the Tampere University Hospital Area in 1980-87, and
information about menstrual cycle was recorded before the operation. Patients operated on dunrng the luteal
phase (days 15-32) had a trend towards a better survival rate (80.4%) than those treated in the follicular
phase (days 1-14) (75.9%). but the difference did not reach statistical significance (P = 0.079). There was a
small difference in the positivity and concentration of hormone receptor proteins, depending on the phase of
the menstrual cycle. A more sensitive analysis found a statistically significant linear association between
survival and day since last menstrual period (LMP) which was not totally accounted for by the variation in
hormone receptor levels during the menstrual cycle or other main prognostic factors (P = 0.018 by Cox's
multivariate regression analysis when LMP was used as a continuous variable). One possible mechanism for
the effect of timing can be that physiological changes related to different phases of menstrual cycle
unfavourably affect the quality of diagnostic and/or treatment procedures. Variation in the lag between the
diagnostic confirmation and the operation of the patient affects the evaluation of such an effect and may
account for the inconsistent results reported so far.
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The effect of menstrual status on the surgical cure of breast
cancer has been studied since Hrushesky and colleagues first
reported their finding that women operated on during their
perimenstrual period had a higher risk of developing metas-
tasis than women operated on at mid-cycle (Hrushesky et al.,
1988, 1989; Ratajczak et al., 1988). Since then several
conflicting results have been published. There is, however, a
lack of biological credibility in the observed differences on
survival owing to the timing of the operation in
premenopausal women (Badwe et al., 1991; Hrushesky, 1991;
Senie et al., 1991). The aim of this study was to evaluate the
effect of the timing of surgery in relation to menstrual cycle
on survival and to assess the confounding effect of other
known prognostic factors.
Materials and methods
Patientpopulation
The patient population is based on the database of the
Steroid Receptor Laboratory (University of Tampere,
Department of Clinical Sciences, Tampere, Finland), which
annually performed 200-300 steroid receptor assays for local
hospitals every year during the study period 1980-87.
Premenopausal breast cancer patients, the date of whose last
menstrual period was recorded by surgeons (available from
60% of patients), entered this study (n = 267). Patients
receiving steroid hormone therapy or whose last menstrual
period had occurred more than 32 days before surgery were
excluded (n = 34). The date of the last menstrual period, the
date of surgery, the size of the primary tumour and steroid
receptor concentrations were provided by the steroid receptor
database. Follow-up data and TNM classification were taken
from the Finnish Cancer Registry (Hakulinen et al., 1981).
The patients were followed for death up to the date (1 July
1992) on which the study closed.
The potential effect of the timing of the operation in
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relation to the menstrual cycle and survival was tested by
grouping the patients by hormone-dependent phases, deter-
mined by the putative time of ovulation 14 days after the last
menstrual period (LMP) approximating the end of the folli-
cular phase. Four phases were used: early follicular (EF)
phase, days 1-7; late follicular (LF) phase, days 8-14; early
luteal (EL) phase, days 15-21; and late luteal (LL) phase,
days 22-32. For some of the analyses the early and late
follicular and luteal phases were merged, and days 1-14 and
15-32 were compared with each other.
The mechanism of the effect on survival of the timing of
the operation in relation to the first day since the last men-
strual period (LMP) was evaluated by correlations with other
hormone-dependent prognostic factors. Multivariate methods
were used to adjust the relationship of first day since LMP to
survival for the other prognostic factors.
Statistical methods
Statistical analyses were done using an IBM-compatible PC
and BMDP statistical software (BMDP Statistical Software,
Los Angeles, CA, USA). Univariate survival analyses were
calculated by the actuarial method and Mantel-Cox statis-
tics were used to test the significance of the survival differ-
ences (BMDP IL). Only cancer deaths were included in the
analysis of survival. Deaths due to other causes (n = 4) were
treated as withdrawals. The Cox proportional hazards model
(BMDP 2L) was used in multivariate analyses of the survival
data and to calculate relative risks.
Results
The 5 year survival of all 445 patients was 70%. The survival
of the 267 patients included in this study did not differ from
that of the 178 premenopausal patients for whom data on
LMP were not available and who were operated on in the
same time period. When the hormone-dependent phase was
used as cut-off, the 5 year survival increased linearly for the
patients with surgery during the early follicular phase sur-
vival to the late luteal phase (Figure 1). Patients operated on
days 15-32 had better 5 year survival than patients operatedEi u- N -cw p
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100.. on days 1-14. The survival rates at 5 years were 80.4% and
90 75.9% respectively (Figure 2).
There were no significant differences in clinical or patho-
80 - I logical features, including tumour size, nodal status and
70 | hormonal receptor status, between the subsets (Table I).
Oestrogen receptor (ER) status was positive in 55% of the
60
- patients operated on days 1-14 and in 53% of the patients
50. EF U EL LLoperated on days 15-32. Progesterone receptor (PR) status
was also independent of the day since LMP (74% vs
40, 73%).
7 14 21 8 he fmquency of ER positivity was somewhat higher in
Days the EF phase, i.e. days 1-7, but the difference was not
1 Overall survival of premenopausal breast cancer significant. The mean concentration of ER for hormone
s by timing the surgery in relation to last menstrual peod receptor-positive cases was also greatest during the EF phase,
folLicular, late follicular, early luteal, late luteal phase). and the mean concentration of PR was highest during the LF
and LL phases (Table II).
The effect of tiing of the operation in relation to the
Follow-up (years)
Fiwe 2 Overall survival of premenopausal breast cancer
patients by timing the surgery in relation to last menstrual period
(LMP 15 vs LMP 14 days).
Tabl- I Distribution of prognostic factors (tumour size, nodal
status, hormone receptor status) between last menstrual period
(LMP) subgroups
LMP 1-14 days LMP 15-32 days
Factor n (%} n (%)
Tumor size
TI 33 (45) 46 (41)
T2 36 (49) 54 (48)
T3 4 (5) 13 (11)
Node
Negative 33 (50) 56 (55)
Positive 33 (50) 45 (45)
Oestrogen
Negative 42 (45) 65 (47)
Positive 52 (55) 74 (53)
Progesterone
Negative 24 (26) 37 (27)
Positive 70 (74) 102 (73)
mstrual phase was not accounted for by the effects ofother
known prognostic factors. In fact, there was a statistically
significant decrease of 1% in the mortality of breast cancer
per day of the operation since the last menstrual period after
adjusting for the other prognostic factors (P = 0.018) (Table
III). The other prognostic factors with statistical significance
were tumour size (P<0.0001), nodal status (P= 0.007) and
PR status (P = 0.068) (Table II).
Dsom
The results of studies on the time of LMP show (Badwe et
al., 1991; Hrushesky, 1991; Senie et al., 1991) or do not show
(Gelber and Goldhih, 1989; Powles et al., 1989, 1991; Ville
et al., 1990, 1991; Low et al., 1991; Mason and Holdaway,
1991; Rageth et al., 1991; Sainsbury et al., 1991) any effect
on the survival of breast cancer patients in relation to the
date of surgery. The studies are retrospective, and menstrual
anamnesis is sometimes poorly recorded in the case notes
(Gruber et al., 1989). Patient series are often small and
heterogeneous, which increases the random error. The most
important confounding factor is likely to be related to the
hormonal cycle itself. Some other prognostic factors can also
confound the results, even if it is unlikely that the date of
operation was correlated with any confounder not related to
the hormonal cycle. Therefore such an explanation has low
credibility. In addition, there is variation in the cut-off-points
of the menstrual period.
Table m Multivariate analysis of the relative risk (RR) (LMP
1-14 days vs LMP 15-32 days) of death due to prognostic factors
of the tumour (size, nodal status, PR status)
Variable RR 95% CI P-vahle
Tumour size (62cm vs >2cm) 2.6 1.3-5.2 <0.0001
Nodal status (N+ vs N-) 2.2 1.2-4.4 0.007
LMP (per day of cycle) 0.99 0.987-0.996 0.018
PR status ( l0fmol vs <IOfmol) 1.9 1.1-3.4 0.068
Table n Distribution and mean concentration of oestrogen and progesterone receptor proteins in
breast cancer during phases of the menstrual cycle
Mean receptor
Receptor status concentration'
Phase of cycle ER- ER+ PR- PR+ (fmolmg-' proteW)
(days) n (%/ n% n n (% ER PR
Early follicular
(1-7) 23 (38) 38 (62) 14 (23) 47 (77) 51 ± 47 184 ± 210
Late follicular
(8-14) 28 (52) 26 (48) 15 (28) 39 (72) 40±39 276+381
Early luteal
(15-21) 29 (51) 28 (49) 16 (28) 41 (72) 32 32 182 174
Late luteal
(22-28) 27 (44) 34 (56) 16 (26) 45 (74) 40 28 251 317
'Positive values only. bValues are the mean ± s.d.
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In our study. patients were asked about their last men-
strual penrod before their operation. and we believe that the
definition of the day of menstrual cycle was exact. The
operation was mastectomy in 95% of the cases. There was no
difference in prognostic factors of clinical importance, includ-
ing node status and tumour size. between the follicular and
luteal phases. Pathological features such as grade of malig-
nancy or histological type were not analysed. Our findings
are consistent with those (Hrushesky et al., 1989; Badwe et
al.. 1991; Hrushesky. 1991: Senie et al., 1991), indicating that
the timing of surgery in relation to the phase of the men-
strual cycle may have an impact on survival. A statistically
significant decrease of 1% in mortality by 1 day since last
menstrual period was observed.
There is a theoretical consideration that hormonal receptor
protein levels can be related to endogenous hormone levels,
depending on the phase of the menstrual cycle. Some inves-
tigators have tried to establish if tumour sex steroid receptors
vary with the phase of the menstrual cycle. Again, results
differ greatly. Some investigators found higher levels during
the proliferative phase (days 1-14) than dunrng the secretory
phase (days 15-32) (Heise and G6rlich, 1982; Axelrod et al..
1988: Smyth et al., 1988). whereas Weimer and Donegan
(1987) measured the highest values in the late luteal phase.
Coradini et al. (1984) reported a higher concentration of
progesterone receptor protein in the early luteal phase (days
16-22). The overall conclusion of previous studies is that
there is no consistent variation in oestrogen receptor protein
levels during the menstrual cycle. We found a higher
prevalence in the positivity of oestrogen receptor protein in
the early follicular phase, and the level of concentration was
also somewhat higher. The progesterone receptor protein
concentration was highest in the late follicular and late luteal
phases, but none of these variations was significant. We were
able to evaluate independently the prognostic value of timing
of surgery by adjusting the effect of hormonal receptor levels
by multivariate analyses. LMP timing in relation to surgery
remained an independent prognostic factor after such an
adjustment.
Other explanations besides those citing hormones have
been also put forward. Malignant cells shed in conditions of
unopposed oestrogen may be more able to proliferate and to
become established as micrometastases than at other times,
or oestrogen may stimulate the release of local growth fac-
tors and proteases (Badwe et al., 1991). Cyclical reductions in
natural killer cell activity before ovulation with a return to
higher levels later in the menstrual cycle have been noted in
studies of healthy women (White et al., 1982). In addition, a
significant decrease has been reported in the phagocytic
activity of mononuclear cells in the early phase of the mens-
trual cycle. Therefore, diminished immune function before
the putative day of ovulation may be one of the mechanisms
(Senie et al., 1991). We do not know of any attempt to
directly evaluate such a hypothesis.
The size, consistency and oedema of the breast and lymph
nodes and the lymph flow vary during the menstrual cycle as
a result of hormonal changes. Such changes in the breast
may cause a variation in the quality of diagnosis and oper-
ation. The inconsistent results reported so far may also be
related to variation in the lag between diagnostic
confirmation and operation. In the Tampere area in 1980-87
most of the diagnostic confirmation was obtained from a
section taken during the operation and frozen.
In their reports McGuire (1991) and McGuire et al. (1992)
have critically discussed the optimal timing of surgery. They
suggest that at least some of the reported results may be
fallacious and due to chance alone. However, they conclude
that not all the differences may be accounted for by random
vanation alone in every study.
Our results are consistent with those showing an effect of
timing of the operation on the survival of breast cancer
patients. Our multivariate analysis implied that the timing of
the operation could not be accounted for by the other prog-
nostic factors. The effect of day since last menstrual period
may be due to correlation of the immune status of the
woman with the menstrual cycle. The variation in survival
may also simply be due to physiological variation in the size
and consistency of breast and lymph nodes at different
phases of the menstrual cycle affecting the ease and quality of
the diagnosis and the operation.
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